-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Popular Articles
-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
Dr. Mariano Provencio said the results could potentially define a standard adjuvant treatment for patients with resectable ES-NSCLC; however, longer-term observation is needed.
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
Dr. David Planchard said the findings support a combination approach as a first-line treatment with an extended overall survival advantage for patients with EGFRm advanced NSCLC.
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
Anti-obesity medications could theoretically reduce the absorption of oral TKIs, particularly in cases of lipophilicity, where therapeutic agents have a strong dependence on dietary fat for adequate dissolution.
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Heidi Nafman-Onda, founder of The White Ribbon Project, shares her experience discovering and grappling with the long-term effects of radiation therapy and addresses the need for coordinated survivorship care.
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
During the session, Dr. Hisao Asamura reviewed the criteria changes in the new 9th edition of the TNM classification recommendations.
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
Dr. Jeffrey D. Bradley presented the data from the phase III study of durvalumab in combination with and following chemoradiotherapy for patients with unresectable, stage III NSCLC during the 2024 European Lung Cancer Congress.
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
IASLC Staging and Prognostic Factors Committee Chair Dr. Hisao Asamura and Drs. Valerie Rusch and Enrico Ruffini summarized the data and recommendations in lung cancer, mesothelioma, and thymic cancer.
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
Mario Lacouture, MD, is director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center and specializes in the dermatologic side effects of cancer treatment. He is the founder of the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary program bringing together patient care, education, and research, and is…
-
A Holistic Approach to Patient Care
Treating the whole patient, not just the disease, is a basic tenet of holistic care. Understanding the physical, emotional, and spiritual needs of patients can help providers provide optimal care and improve outcomes. Stress comes in many forms, and some patients need help building resilience and stress-management skills. A New Approach to Assessing Patients’ Fitness…